LAUREN WHALEN: Open Payments
NPI 1194159517 · MIDDLETOWN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$875 in 34 payments from 16 companies in 2025. Trend: 2023 $2,074 · 2024 $2,131 · 2025 $875
Food & beverage: $875
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $152 |
| Incyte Corporation | 2 | $139 |
| AstraZeneca Pharmaceuticals LP | 2 | $138 |
| GENZYME CORPORATION | 4 | $93 |
| Novartis Pharmaceuticals Corporation | 2 | $53 |
| Galderma Laboratories, L.P. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| PFIZER INC. | 1 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $29 |
| CSL Behring | 1 | $27 |
Products named: NUCALA, TEZSPIRE, Opzelura, DUPIXENT, NEMLUVIO, CUVITRU, CIBINQO, NEFFY.
Industry payments across NY — which companies pay providers there.
